Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-03-04

FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA approves a supplemental application for MYRBETRIQ (mirabegron) by Astellas Pharma US, expanding the drug's label.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Myrbetriq (mirabegron)

Snippet

SUPPL AP for MYRBETRIQ (MIRABEGRON)